These are top 10 stocks traded on the Robinhood UK platform in July
Haleon plc (LSE/NYSE: HLN), the leading consumer health company with a market capitalization of $46.7 billion, has announced its Annual General Meeting (AGM) will be held virtually on Wednesday, May 28, 2025. Shareholders are invited to attend the meeting, which will be broadcast from the company’s London offices at 3:00 pm BST. According to InvestingPro, the company maintains a "GREAT" financial health score, reflecting its strong market position.
The company, known for brands like Advil, Sensodyne, and Centrum, stated that the Notice of the 2025 AGM, along with the Form of Proxy and AGM Voting Instruction Card, are now available to shareholders. These documents can be accessed on Haleon’s website, as described in the Notice, which includes full details on the business to be discussed and instructions for joining the virtual event. With a robust gross profit margin of 63.2% and annual revenue of $14.1 billion, Haleon continues to demonstrate strong operational performance.
In accordance with UK Listing Rule 6.4.1R, Haleon has submitted these documents to the National Storage Mechanism, and they will soon be available for public inspection.
Today’s announcement by Haleon is in line with the company’s commitment to maintaining transparency with its investors and ensuring shareholder participation in corporate governance, despite the ongoing preference for virtual meetings.
The AGM is expected to cover a range of topics pertinent to the company’s operations and strategy. However, specific details of the resolutions to be proposed at the meeting have not been disclosed in this announcement.
This news is based on a press release statement and serves as an essential update for investors and market watchers, particularly those with an interest in Haleon (LSE/NYSE: HLN). The company, with its focus on products across major health categories, continues to emphasize its dedication to delivering better everyday health with humanity. Investors should note that Haleon offers a dividend yield of 2.23% and is scheduled to report earnings on April 30, 2025. For detailed financial analysis and additional insights, check out the comprehensive research report available on InvestingPro, which provides in-depth coverage of this prominent player in the pharmaceuticals industry.
For further inquiries, Haleon has provided contact information for both investor relations and media communications, ensuring that stakeholders can seek additional information as needed.
In other recent news, Haleon plc has launched a £330 million share buyback program, aiming to enhance shareholder returns and potentially improve earnings per share. This initiative follows the completion of an off-market share repurchase from Pfizer Inc. (NYSE:PFE), resulting in the cancellation of 44,155,844 shares. This transaction has adjusted the total issued share count to 9,039,570,075, with 9,035,489,870 shares carrying voting rights. Haleon has also updated its share count and voting rights, emphasizing transparency for shareholders under the Financial Conduct Authority’s rules.
In addition, Haleon has disclosed the granting of conditional share awards to its executives, aligning their compensation with company performance. CEO Brian McNamara received a significant portion of these awards, which are contingent on performance conditions to be evaluated by the end of 2027. Furthermore, Haleon has published its 2024 Annual Report and Form 20-F, offering a detailed view of its financial performance and product portfolio. The report is available for public inspection, and shareholders can request physical copies. These developments reflect Haleon’s ongoing efforts to manage its capital effectively and maintain transparency in its operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.